- Home
- GFS vs GMAB Comparison
GFS vs GMAB Comparison
Compare GFS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFS
- GMAB
- Stock Information
- Founded
- GFS 2009
- GMAB 1999
- Country
- GFS United States
- GMAB Denmark
- Employees
- GFS N/A
- GMAB N/A
- Industry
- GFS Semiconductors
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GFS Technology
- GMAB Health Care
- Exchange
- GFS Nasdaq
- GMAB Nasdaq
- Market Cap
- GFS 18.5B
- GMAB 17.4B
- IPO Year
- GFS 2021
- GMAB N/A
- Fundamental
- Price
- GFS $33.98
- GMAB $30.56
- Analyst Decision
- GFS Buy
- GMAB Strong Buy
- Analyst Count
- GFS 8
- GMAB 6
- Target Price
- GFS $41.38
- GMAB $40.40
- AVG Volume (30 Days)
- GFS 3.0M
- GMAB 2.5M
- Earning Date
- GFS 11-12-2025
- GMAB 11-06-2025
- Dividend Yield
- GFS N/A
- GMAB N/A
- EPS Growth
- GFS N/A
- GMAB 132.41
- EPS
- GFS N/A
- GMAB 25.10
- Revenue
- GFS $6,791,000,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- GFS $1.04
- GMAB $24.92
- Revenue Next Year
- GFS $8.15
- GMAB $15.97
- P/E Ratio
- GFS N/A
- GMAB $1.21
- Revenue Growth
- GFS 0.25
- GMAB 29.57
- 52 Week Low
- GFS $29.77
- GMAB $17.24
- 52 Week High
- GFS $47.69
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- GFS 45.43
- GMAB 58.36
- Support Level
- GFS $32.64
- GMAB $28.08
- Resistance Level
- GFS $35.90
- GMAB $29.35
- Average True Range (ATR)
- GFS 1.49
- GMAB 0.69
- MACD
- GFS -0.13
- GMAB 0.03
- Stochastic Oscillator
- GFS 36.60
- GMAB 95.93
About GFS GlobalFoundries Inc.
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.